Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.

Spiazzi BF, Zingano CP, Colpani V, Gerchman F

Diabetes research and clinical practice13 Jul 2026

PMID42442557DOI10.1016/j.diabres.2026.113431PepBankPUB-42442557

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes or overweight/obesity, tirzepatide was associated with fewer MACE in a meta-analysis of randomised trials.
In plain wordsIn adults with type 2 diabetes or overweight/obesity, tirzepatide was linked to fewer serious heart events in trials.
Peptide
Tirzepatide
Outcome
DecreaseMajor adverse cardiovascular events (MACE)
Study
n = 29,023
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
OR
0.87 ratio
MACE
Source sentences
Summary
Tirzepatide was associated with a reduction in MACE (OR 0.87, 95% CI 0.79-0.94; high certainty); TSA estimated that sample size was sufficient for definitive conclusions.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks.
Summary · context
We included 22 trials encompassing 29,023 participants.
Report a problemFND-4244255701
02HumanSystematic reviewEfficacy outcome
In the meta-analysis, each 1 mg increase in tirzepatide dose was associated with 2.8% lower odds of MACE.
In plain wordsIn trials of adults with type 2 diabetes or overweight/obesity, higher tirzepatide doses were linked to lower odds of serious heart events.
Peptide
Tirzepatide
Outcome
DecreaseDose-response for MACE
Study
n = 29,023
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Lower odds of MACE per 1 mg dose increase
2.8%
dose-response
Source sentences
Summary
A dose-response association was observed, with 2.8% lower odds of MACE for every 1 mg increase in tirzepatide dose.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks.
Summary · context
We included 22 trials encompassing 29,023 participants.
Report a problemFND-4244255702
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes or overweight/obesity, tirzepatide was associated with lower all-cause mortality in the meta-analysis.
In plain wordsIn adults with type 2 diabetes or overweight/obesity, tirzepatide was linked to fewer deaths from any cause in trials.
Peptide
Tirzepatide
Outcome
DecreaseAll-cause mortality
Study
n = 29,023
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
OR
0.84 ratio
all-cause mortality
Source sentences
Summary
Tirzepatide was associated with a reduction in all-cause mortality (OR 0.84, 95% CI 0.75-0.93)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks.
Summary · context
We included 22 trials encompassing 29,023 participants.
Report a problemFND-4244255703
04HumanSystematic reviewEfficacy outcome
In the meta-analysis, tirzepatide showed no association with individual components of MACE.
In plain wordsIn trials, tirzepatide showed no clear link to any single type of serious heart event on its own.
Peptide
Tirzepatide
Outcome
No significant changeIndividual MACE components
Study
n = 29,023
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
no association was observed for individual components of MACE or heart failure hospitalizations.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks.
Summary · context
We included 22 trials encompassing 29,023 participants.
Report a problemFND-4244255704
05HumanSystematic reviewEfficacy outcome
In the meta-analysis, tirzepatide showed no association with heart failure hospitalizations.
In plain wordsIn trials, tirzepatide showed no clear link to fewer hospital stays for heart failure.
Peptide
Tirzepatide
Outcome
No significant changeHeart failure hospitalizations
Study
n = 29,023
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
no association was observed for individual components of MACE or heart failure hospitalizations.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks.
Summary · context
We included 22 trials encompassing 29,023 participants.
Report a problemFND-4244255705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.